605 related articles for article (PubMed ID: 17767166)
1. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST; Zhang L; Martenyi F; Lowe SL; Jackson KA; Andreev BV; Avedisova AS; Bardenstein LM; Gurovich IY; Morozova MA; Mosolov SN; Neznanov NG; Reznik AM; Smulevich AB; Tochilov VA; Johnson BG; Monn JA; Schoepp DD
Nat Med; 2007 Sep; 13(9):1102-7. PubMed ID: 17767166
[TBL] [Abstract][Full Text] [Related]
2. [The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
Mosolov SN; Smulevich AB; Neznanov NG; Tochilov VA; Andreev BV; Avedisova AS; Bardenshteĭn LM; Gurovich IIa; Reznik AM; Zharkova NB; Martenyi F
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):16-23. PubMed ID: 20639852
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Rorick-Kehn LM; Johnson BG; Knitowski KM; Salhoff CR; Witkin JM; Perry KW; Griffey KI; Tizzano JP; Monn JA; McKinzie DL; Schoepp DD
Psychopharmacology (Berl); 2007 Jul; 193(1):121-36. PubMed ID: 17384937
[TBL] [Abstract][Full Text] [Related]
7. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.
Kinon BJ; Millen BA; Zhang L; McKinzie DL
Biol Psychiatry; 2015 Dec; 78(11):754-62. PubMed ID: 25890643
[TBL] [Abstract][Full Text] [Related]
8. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
Chaki S; Yoshida S; Okuyama S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
[TBL] [Abstract][Full Text] [Related]
9. Toward illness phase-specific pharmacotherapy for schizophrenia.
Krystal JH; Anticevic A
Biol Psychiatry; 2015 Dec; 78(11):738-40. PubMed ID: 26542740
[No Abstract] [Full Text] [Related]
10. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Fell MJ; McKinzie DL; Monn JA; Svensson KA
Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of mGlu
Metcalf CS; Klein BD; Smith MD; Pruess T; Ceusters M; Lavreysen H; Pype S; Van Osselaer N; Twyman R; White HS
Epilepsia; 2017 Mar; 58(3):484-493. PubMed ID: 28166368
[TBL] [Abstract][Full Text] [Related]
12. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
[TBL] [Abstract][Full Text] [Related]
13. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Galici R; Echemendia NG; Rodriguez AL; Conn PJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
[TBL] [Abstract][Full Text] [Related]
14. Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.
Dedeurwaerdere S; Wintmolders C; Straetemans R; Pemberton D; Langlois X
Psychopharmacology (Berl); 2011 Mar; 214(2):505-14. PubMed ID: 21057775
[TBL] [Abstract][Full Text] [Related]
15. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.
Mezler M; Geneste H; Gault L; Marek GJ
Curr Opin Investig Drugs; 2010 Jul; 11(7):833-45. PubMed ID: 20571979
[TBL] [Abstract][Full Text] [Related]
16. When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy.
Marek GJ
Curr Pharm Des; 2015; 21(26):3788-96. PubMed ID: 26044978
[TBL] [Abstract][Full Text] [Related]
17. Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Lowe S; Dean R; Ackermann B; Jackson K; Natanegara F; Anderson S; Eckstein J; Yuen E; Ayan-Oshodi M; Ho M; McKinzie D; Perry K; Svensson K
Psychopharmacology (Berl); 2012 Feb; 219(4):959-70. PubMed ID: 21847569
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.
Liu W; Downing AC; Munsie LM; Chen P; Reed MR; Ruble CL; Landschulz KT; Kinon BJ; Nisenbaum LK
Pharmacogenomics J; 2012 Jun; 12(3):246-54. PubMed ID: 21173788
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
Monn JA; Massey SM; Valli MJ; Henry SS; Stephenson GA; Bures M; Hérin M; Catlow J; Giera D; Wright RA; Johnson BG; Andis SL; Kingston A; Schoepp DD
J Med Chem; 2007 Jan; 50(2):233-40. PubMed ID: 17228865
[TBL] [Abstract][Full Text] [Related]
20. Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.
Ahnaou A; Biermans R; Drinkenburg WH
PLoS One; 2016; 11(1):e0147365. PubMed ID: 26808689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
